TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29727545

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mid-frequency transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM) + Mid-frequency TEAS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (TAM and TEAS)
Number of subjects: 120
Study: 25906559

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with transperineal injection of 200 IU BTX-A
Number of subjects: 35

Group type: COMPARATOR
Intervention: Transperineal injection of 200 IU BTX-A
Number of subjects: 35
Study: 24143017

Group type: EXPERIMENTAL
Intervention: Coarse CAPs (200 µg/m(3))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Fine CAPs (250 µg/m(3))
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Endotoxin (5.4 ng/m(3))
Number of subjects: 35

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 35

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 35
Study: 21148044

Group type: EXPERIMENTAL
Intervention: Combination tablet of alendronate/vitamin D(3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ALN 70 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D(3) alone
Number of subjects: 0
Study: 19664769

Group type: EXPERIMENTAL
Intervention: Meperidine (50 mg)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Valethamate bromide (16 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 160
Study: 17175376

Group type: EXPERIMENTAL
Intervention: CA repeat polymorphism in the EGFR gene
Number of subjects: 0
Study: 15135191

Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endotracheal intubation (ETI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bag-valve mask (BVM)
Number of subjects: 60
Study: 11789320

Group type: EXPERIMENTAL
Intervention: Huang Qi Gu Jing Yin (HQGJY)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 30
Study: 9417487

Group type: EXPERIMENTAL
Intervention: Parenteral selenium supplementation (week 1: twice 500 micrograms daily, week 2: once 500 micrograms, week 3: three times 100 micrograms sodium selenite)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Parenteral selenium supplementation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no selenium supplementation)
Number of subjects: 24
Study: 7679737

Group type: EXPERIMENTAL
Intervention: Naltrexone (12.5 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hydromorphone (0.75, 1.5 and 3 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pentazocine (15, 30 and 60 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 2867610

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 51
Study: 30833436

Group type: EXPERIMENTAL
Intervention: Irinotecan (150 mg/m2) administered intravenously over 90 min on day 1, and S-1 (80 mg/m2) given orally in two divided doses from days 1 to 14 of a 21 day cycle.
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Irinotecan plus S-1
Number of subjects: 19
Study: 30954164

Group type: EXPERIMENTAL
Intervention: Venous coupler
Number of subjects: 124

Group type: COMPARATOR
Intervention: Hand-sewn anastomosis
Number of subjects: 124
Study: 26549803

Group type: EXPERIMENTAL
Intervention: Perforated membranes (PM)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Open flap debridement (OFD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Occlusive membrane (OM)
Number of subjects: 30
Study: 23979497

Group type: EXPERIMENTAL
Intervention: HIV/STI intervention
Number of subjects: 848

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 848
Study: 22326480

Group type: EXPERIMENTAL
Intervention: Progressive, tailored multimodal exercise program in addition to the standard osteoporosis exercise program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard osteoporosis exercise program alone
Number of subjects: 41
Study: 21047625

Group type: EXPERIMENTAL
Intervention: Non-search paradigm testing with an agent demonstrating a rattling object
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inference and memory-based prompts in the non-search paradigm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional results from Experiment 3
Number of subjects: 0
Study: 17984395

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs) including olanzapine, quetiapine fumarate, risperidone
Number of subjects: 421

Group type: COMPARATOR
Intervention: Placebo (representing a 'watchful waiting' treatment strategy)
Number of subjects: 421
Study: 15759023

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty
Number of subjects: 106

Group type: COMPARATOR
Intervention: Antihypertensive drug therapy
Number of subjects: 106
Study: 14638565

Group type: EXPERIMENTAL
Intervention: Weekly patient self-management with phenprocoumon
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Weekly management at an anticoagulation clinic with phenprocoumon
Number of subjects: 341

Group type: COMPARATOR
Intervention: Existing routine care group (untrained in self-management)
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Weekly management with acenocoumarol
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Routine care group of trained patients
Number of subjects: 341
Study: 10823572

Group type: EXPERIMENTAL
Intervention: Mandatory vaccination program for HCWs (intramuscular half dose from 1990 to 1995, intradermal from 1983 to 1989)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mandatory vaccination program for high-risk workers
Number of subjects: 0
Study: 8654109

Group type: EXPERIMENTAL
Intervention: Lensmeter 701 (LOM)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Lens Opacities Classification System II (LOCS II)
Number of subjects: 410
Study: 1626674

Group type: EXPERIMENTAL
Intervention: Lignocaine at a dose of 0.2 mg.kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study: 6093979

Group type: EXPERIMENTAL
Intervention: High-dose CAV (HD-CAV) - cyclophosphamide 1200 mg/m2, doxorubicin 70 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21
Number of subjects: 293

Group type: COMPARATOR
Intervention: Conventional-dose CAV + VP-16 (CAV-VP) - cyclophosphamide 1000 mg/m2, doxorubicin 40 mg/m2, vincristine 1 mg/m2 IV on days 1 and 21 with VP-16 100 mg/m2 on days 1-3 and 21-23
Number of subjects: 293
Study: 3742319

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg PO the night prior to surgery and 300 mg IV 30 minutes prior to anaesthesia induction (Part 1)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Cimetidine continued for 24 hours into the postoperative period (Part 2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (Part 1)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (Part 2)
Number of subjects: 62
Study: 29550085

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg once daily plus a P2Y12 inhibitor
Number of subjects: 2124

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily plus dual antiplatelet therapy (DAPT)
Number of subjects: 2124

Group type: COMPARATOR
Intervention: Dose-adjusted warfarin plus DAPT
Number of subjects: 2124
Study: 28264695

Group type: EXPERIMENTAL
Intervention: Dietary and physical activity intervention
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Data collection methods
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Recommendations for future trials
Number of subjects: 17
Study: 26409410

Group type: COMPARATOR
Intervention: High-frequency rTMS (90% of resting motor threshold, 10 Hz, 1,000 pulses) applied over the lower leg primary motor cortex (M1-LL) for five sessions in a week.
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham stimulation (control condition) with a two-week wash out period.
Number of subjects: 17
Study: 24171782

Group type: EXPERIMENTAL
Intervention: Individualized acupuncture point prescriptions, 20 sessions over four weeks.
Number of subjects: 249

Group type: COMPARATOR
Intervention: Non-acupoint control group, 20 sessions over four weeks.
Number of subjects: 249

Group type: COMPARATOR
Intervention: Waiting-list control group, no treatment for 24 weeks, followed by 20 acupuncture treatments for free.
Number of subjects: 249
Study: 21380966

Group type: EXPERIMENTAL
Intervention: Negative loading (NLG)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Positive loading (PLG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 32
Study: 18312057

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day for 10 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 19
Study: 17025273

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, subcutaneous doses of 0.5 microg/kg every week to 15 microg/kg every 3 weeks
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, intravenous and subcutaneous doses of 2.25 microg/kg every week and 6.75 microg/kg every 3 weeks
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa, subcutaneous doses
Number of subjects: 573

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 573
Study: 12958395

Group type: EXPERIMENTAL
Intervention: Advance
Number of subjects: 12

Group type: COMPARATOR
Intervention: Own brand
Number of subjects: 12

Group type: COMPARATOR
Intervention: No cigarettes
Number of subjects: 12
Study: 10945387

Group type: EXPERIMENTAL
Intervention: Intermittent bolus infusions of 1,000 IU AT III every 4 h for 4 days (total dose: 30,000 IU AT III)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Continuous infusion of 250 IU AT III/h for 4 days (total dose: 30,000 IU AT III)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both regimens (Intermittent bolus and Continuous infusion)
Number of subjects: 33
Study: 8930434

Group type: EXPERIMENTAL
Intervention: Fosphenytoin (Cerebyx)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Phenytoin (Dilantin)
Number of subjects: 52
Study: 1532964

Group type: EXPERIMENTAL
Intervention: Lithium succinate ointment (8%)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study: 3902527

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (24 h prophylaxis)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Cefazolin sodium (48 h prophylaxis)
Number of subjects: 206
Study: 31000320

Group type: EXPERIMENTAL
Intervention: Amino acid supplement with HMB 1200mg, l‐glutamine 7000mg, and l‐arginine 7000mg administered once or twice per day for 14‐28 days preoperatively.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nutritional intervention)
Number of subjects: 0
Study: 29095655

Group type: EXPERIMENTAL
Intervention: Intervention group (9 strengthening and 9 stretching exercises, performed during warm-up or at home)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 305
Study: 27465872

Group type: EXPERIMENTAL
Intervention: Preoperative intracavitary irradiation (PII)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NACT)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Radical hysterectomy (RH)
Number of subjects: 133
Study: 25369857

Group type: EXPERIMENTAL
Intervention: Integrated smoking cessation and alcohol intervention
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Smoking cessation only intervention
Number of subjects: 1350
Study: 22355008

Group type: EXPERIMENTAL
Intervention: Computerized Stroop‐like token task with increased WMC demands
Number of subjects: 32
Study: 19789375

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study: 18603157

Group type: EXPERIMENTAL
Intervention: Usual care plus the intervention (nurse-delivered complex intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Usual care plus the intervention
Number of subjects: 200
Study: 16048622

Group type: EXPERIMENTAL
Intervention: Facilitated Case Discussion (FCD)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Computerised Tutorial (CT)
Number of subjects: 46
Study: 12805389

Group type: EXPERIMENTAL
Intervention: 4-month weight-loss program including 10 weeks on a very-low-energy diet (VLED) and 17 behavior modification visits
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group with no intervention
Number of subjects: 38
Study: 10192481

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 200
Study: 8531105

Group type: EXPERIMENTAL
Intervention: isoproterenol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: atropine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: norepinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: propranolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: verapamil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: adenosine
Number of subjects: 20
Study: 1708969

Group type: EXPERIMENTAL
Intervention: Prednisone (2 mg/kg/24 h in three divided doses)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 389978

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31437228

Group type: EXPERIMENTAL
Intervention: PBS-based staff training
Number of subjects: 63
Study: 28712681

Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Usual job search advice (Control)
Number of subjects: 199
Study: 25475116

Group type: EXPERIMENTAL
Intervention: 1 mg nitisinone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg nitisinone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 4 mg nitisinone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 8 mg nitisinone
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 24908550

Group type: EXPERIMENTAL
Intervention: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir (switch group)
Number of subjects: 439

Group type: COMPARATOR
Intervention: NNRTI plus emtricitabine and tenofovir (no-switch group)
Number of subjects: 439
Study: 22226170

Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Transfemoral approach (TFA)
Number of subjects: 303
Study: 18622618

Group type: EXPERIMENTAL
Intervention: Ipsilateral rotational keratoplasty (IRK) and cataract extraction
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Postoperative spherical refraction
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Uncontrolled keratitis
Number of subjects: 17
Study: 17488502

Group type: EXPERIMENTAL
Intervention: Neuromuscular training 3x/week over a 7-week period for high-risk athletes
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (4 subjects classified as high-risk and 7 classified as low-risk)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Neuromuscular training for low-risk athletes
Number of subjects: 24
Study: 15008864

Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment
Number of subjects: 20
Study: 11591618

Group type: EXPERIMENTAL
Intervention: Angiotensin I (Ang I)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: [Pro(11)(D)‐Ala(12)] Ang I
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril (6.25 mg oral dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9723821

Group type: EXPERIMENTAL
Intervention: meloxicam 15 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: piroxicam 20 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study: 7849250

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 100 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg thrice daily added to thiazide and placebo regimens
Number of subjects: 24
Study: 2974770

Group type: EXPERIMENTAL
Intervention: Electrocardiographic criteria based on chest lead voltages
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Electrocardiographic criteria based on limb lead voltages
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All electrocardiographic criteria
Number of subjects: 100
Study: 29383503

Group type: EXPERIMENTAL
Intervention: Total Synovectomy (TS)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Limited Synovectomy
Number of subjects: 148
Study: 27156189

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg once daily for 3 days
Number of subjects: 754

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 754

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 754
Study: 24595224

Group type: EXPERIMENTAL
Intervention: Concentrated arabinoxylan combined with rye kernels (AXRK)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Concentrated arabinoxylan (AX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control meal (semolina porridge, SE)
Number of subjects: 15
Study: 22008873

Group type: COMPARATOR
Intervention: Natalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natalizumab + IFNβ‐1a
Number of subjects: 0
Study: 20473070

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 17851902

Group type: EXPERIMENTAL
Intervention: Ménière's disease group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 16547387

Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus group
Number of subjects: 60
Study: 12381983

Group type: EXPERIMENTAL
Intervention: Manipulation under anesthesia (MUA)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Traditional chiropractic treatment (nonintervention group)
Number of subjects: 87
Study: 8536868

Group type: EXPERIMENTAL
Intervention: New treatments for inflammatory bowel disease (specific interventions not detailed in the abstract)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trials methodology
Number of subjects: 0
Study: 2180981

Group type: EXPERIMENTAL
Intervention: Biosynthetic human GH treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Surgery for acromegaly
Number of subjects: 30
Study: 543202

Group type: EXPERIMENTAL
Intervention: 200 mg/day Perhexilinmaleat
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 400 mg/day Perhexilinmaleat
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31021278

Group type: EXPERIMENTAL
Intervention: Beetroot (BR) juice supplementation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL) juice
Number of subjects: 8
Study: 28364270

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both bisoprolol and ramipril
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25633470

Group type: EXPERIMENTAL
Intervention: Modifying Phonation Intervals (MPI) treatment
Number of subjects: 27

Group type: COMPARATOR
Intervention: Prolonged speech treatment
Number of subjects: 27
Study: 23989747

Group type: EXPERIMENTAL
Intervention: Pre-operative expectations of improvement in pain and health status measured using 100 mm visual analogue scales (VAS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-operative satisfaction ratings using 100 mm VAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Importance attached to recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence in achieving expected results
Number of subjects: 0
Study: 20082130

Group type: EXPERIMENTAL
Intervention: Integrated behavioral intervention
Number of subjects: 819

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 819
Study: 19595803

Group type: EXPERIMENTAL
Intervention: Aspiration and sclerotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hydrocelectomy
Number of subjects: 60
Study: 17987114

Group type: EXPERIMENTAL
Intervention: 4% dimeticone lotion
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.5% malathion liquid
Number of subjects: 73
Study: 15188980

Group type: EXPERIMENTAL
Intervention: Expressed breast milk (EBM) 5 ml
Number of subjects: 81

Group type: COMPARATOR
Intervention: Distilled water (DW) 5 ml (placebo)
Number of subjects: 81
Study: 11480129

Group type: EXPERIMENTAL
Intervention: Pioglitazone (Actos), specific dosage and duration not mentioned
Number of subjects: 0
Study: 10452408

Group type: EXPERIMENTAL
Intervention: Butter oil and low erucic rapeseed oil (65:35) (BR)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Butter blended in a 1:1 ratio with an interesterified mixture of rapeseed oil and fully hydrogenated rapeseed oil (70:30) (BS)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Butter/grapeseed oil (90:10) (BG)
Number of subjects: 13
Study: 7645110

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0